4-(tetrazol-5-yl)-quinazoline derivatives as anti-cancer agent

Details 4-(tetrazol-5-yl)-quinazoline derivatives as anti-cancer agent 4-(tetrazol-5-yl)-quinazoline derivatives as anti-cancer agent

2008-10-28

2011-12-20

Wilson, James O (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S284000

Reexamination Certificate

active

08080558

ABSTRACT:
The invention relates to substituted 4-(tetrazol-5-yl)-quinazoline derivatives of the formula-I,or pharmaceutically-acceptable salts thereof, which possess anti-proliferative activity such as anti-cancer activity and are accordingly useful in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of substituted 4-(tetrazol-5-yl)-quinazoline derivatives, to pharmaceutical compositions containing the compound and to its use in the manufacture of medicaments for the production of an anti-proliferative effect in a warm-blooded animal such as man.

REFERENCES:
patent: 3800039 (1974-03-01), Marquis et al.
patent: 5747498 (1998-05-01), Schnur et al.
patent: 5770599 (1998-06-01), Gibson
patent: 2004/0048880 (2004-03-01), Himmelsbach et al.
patent: 0 211 363 (1987-02-01), None
patent: 0 304 493 (1989-03-01), None
patent: 0 322 738 (1989-07-01), None
patent: 0 400 586 (1990-12-01), None
patent: 0 520 722 (1992-12-01), None
patent: 0 566 226 (1993-10-01), None
patent: 0 602 851 (1994-06-01), None
patent: 0 635 498 (1995-01-01), None
patent: WO 92/20642 (1992-11-01), None
patent: WO 96/09294 (1996-03-01), None
patent: WO 96/15118 (1996-05-01), None
patent: WO 96/16960 (1996-06-01), None
patent: WO 96/30347 (1996-10-01), None
patent: WO 96/33977 (1996-10-01), None
patent: WO 96/33978 (1996-10-01), None
patent: WO 96/33979 (1996-10-01), None
patent: WO 96/33980 (1996-10-01), None
patent: WO 96/33981 (1996-10-01), None
patent: WO 97/03069 (1997-01-01), None
patent: WO 97/13771 (1997-04-01), None
patent: WO 97/30034 (1997-08-01), None
patent: WO 97/30035 (1997-08-01), None
patent: WO 97/38983 (1997-10-01), None
patent: WO 98/02434 (1998-01-01), None
patent: WO 98/02437 (1998-01-01), None
patent: WO 98/02438 (1998-01-01), None
patent: WO 98/13354 (1998-04-01), None
patent: WO 99/35132 (1999-07-01), None
patent: WO 99/35146 (1999-07-01), None
patent: WO 01/21596 (2001-03-01), None
patent: WO 01/55141 (2001-08-01), None
patent: WO 01/94341 (2001-12-01), None
patent: WO 02/18372 (2002-03-01), None
patent: WO 03/040108 (2003-05-01), None
patent: WO 03/040109 (2003-05-01), None
patent: WO 2004/046101 (2004-03-01), None
patent: WO 2004/093880 (2004-11-01), None
patent: WO 2005/051923 (2005-06-01), None
patent: WO 2008/012326 (2008-01-01), None
Bokemeyer et al., “Angiotensin II-induced growth of vascular smooth muscle cells requires an Src-dependent activation of the epidermal growth factor receptor,”Kidney International(2000) 58: 549-558.
Yaish et al., “Locking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors,”Science(1988) 242 (4880): 933-935.
Toi et al., “Antineoplastic effect of erbstatin on human mammary and esophageal tumors in athymic nude mice,”Eur. J. Cancer(1990) 16 (6): 722-724.
Yoneda et al., “The antiproliferative effects of tyrosin kinase inhibitors tyrphostins on a human squamous cell carcinoma in Vitro and in nude mice,”Cancer Research(1991) 51: 4430-4435.
Burke, Jr., T.R., “Protein-tyrosine kinase inhibitors,”Drugs of the Future(1992) 17 (2): 119-131.
Fry et al., “A specific inhibitor of the epidermal growth factor receptor tyrosine kinase,”Science(1994) 265: 1093-1095.
Mendelsohn et al., “The EGF receptor family as targets for cancer therapy,”Oncogene(2000) 19: 6550-6565.
Lynch et al., “Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitnib,”New England Journal of Medicine(2004) 350: 2129-2139.
Paez et al., “EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy,”Science(2004) 304: 1497-1500.
Sordella et al., “Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways,”Science(2004) 305: 1163-1167.
Stephens et al., “Intragenic ERBB2 kinase mutations in tumours,”Nature(2004) 431: 525-526.
Kant et al., “Preparation and reactions of mono-reissert compounds and analogs at the 3,4-position of quinazoline [1],”J. Heterocyclic Chem. (1985) 22: 1313-1316. XP009114027.
Miyashita et al., “Preparation of heteroarenecarbonitriles by reaction of the heteroareneN-oxides with trimethylsilyl cyanide in the presence of DBU,”Heterocycles(1992) 33 (1): 211-216.

Affiliated with

Also associated with

Rating

4-(tetrazol-5-yl)-quinazoline derivatives as anti-cancer agent does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 4-(tetrazol-5-yl)-quinazoline derivatives as anti-cancer agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-(tetrazol-5-yl)-quinazoline derivatives as anti-cancer agent will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4296528